Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, have historically been considered more prevalent in developed regions such as North America and Europe. However, recent global data, including large-scale analyses published in Nature, reveal clear epidemiological shifts: IBD is now spreading rapidly in developing and middle-income regions across Asia, Africa, and Latin America. This transition follows a predictable pattern of disease development and places increasing pressure on healthcare systems that are not yet fully prepared to manage its complexity.

As a developing middle-income country with an evolving healthcare system, Azerbaijan is currently in the early stages of this process. Clinical experience in IBD remains limited, and structured training opportunities for managing advanced stages of the disease are still being established. At the same time, the global landscape of IBD treatment has changed dramatically over the past 20 years. The introduction of biologics and new small-molecule drugs has revolutionized therapy, offering diverse mechanisms of action and increasingly personalized approaches. While these innovations improve patient outcomes, they have also significantly increased the complexity of clinical decision-making.

Effective modern IBD management requires broad and deep expertise. This includes selecting appropriate advanced treatment strategies, monitoring therapy, managing drug side effects and paradoxical reactions, performing endoscopic assessments and interventions, and determining surgical indications in collaboration with surgeons. Nonetheless, international studies show that even in well-established training systems, many physicians report feeling insufficiently prepared to manage complex IBD cases and have low confidence in their skills.

Countries like Germany have established highly specialized IBD centers where concentrated expertise is supported by strong, continuously updated clinical guidelines. The presence of nearly 3,000 Azerbaijani physicians in Germany and their collaboration with local healthcare professionals provides an opportunity for Azerbaijan to benefit from this experience.

The proposed IBD Network aims to bridge this gap and strengthen local capacity by leveraging Germany’s clinical expertise. Through structured educational programs, CME courses, and collaborative training models, the initiative seeks to enhance physicians’ knowledge, develop clinical skills, and support the establishment of standardized, high-quality IBD care in Azerbaijan. By proactively addressing current educational gaps and preparing physicians for the growing IBD burden, this initiative will contribute to improved patient outcomes in the region and the development of a more resilient healthcare system.